Drug Trial Radar · NCT04630522
Efficacy and Safety of JMT103 in Patients With Bone Metastases From Solid Tumors
Last checked: Nov 19, 2026Latest source record: Nov 9, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
295
Actual
Start
Oct 31, 2020
Primary completion
Mar 31, 2023
Study completion Mar 31, 2023
Sponsor
- Lead sponsor
- Shanghai JMT-Bio Inc.Industry
- Sponsor type
- Industry
- First posted
- Nov 16, 2020
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a randomized, open-label, dose-finding, multi-centre, phase Ⅰb study to evaluate the efficacy and safety of JMT103 in patients with bone metastases from solid tumors.
Conditions
- Bone Metastases From Solid Tumors
Interventions
Drug: JMT103- 120 mg SC Q4WDrug
JMT103 is administered subcutaneously at a dose of 120 mg on day 1 of each 4-week cycle.
Drug: JMT103- 120 mg SC Q8WDrug
JMT103 is administered subcutaneously at a dose of 120 mg on day 1 of each 8-week cycle.
Drug: JMT103- 180 mg SC Q8WDrug
JMT103 is administered subcutaneously at a dose of 180 mg on day 1 of each 8-week cycle.
Dietary Supplement: Calcium Dietary Supplement: Vitamin DDietary supplement
Calcium is given orally at a dose of 500 mg at least, once daily. Vitamin D is given orally at a dose of 400 IU at least, once daily.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage change of urinary N-terminal telopeptide of type 1 collagen/creatine (U-NTX/Cr) from baseline to week 13Time frame: From enrollment to week 13.
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Shanghai East Hospital
Shanghai, Shanghai Municipality, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.